Training Scope

This program provides a complete and integrated framework for applying Six Sigma methodologies within pharmaceutical and biologics manufacturing environments. Biologics, including vaccines, gene therapies, monoclonal antibodies, and recombinant proteins, present unique challenges due to their complex molecular structures, sensitivity to environmental conditions, and the inherent variability of living systems used in their production. The curriculum synthesizes classical statistical process control, strategic quality management, organizational change principles, and practical project execution, specifically tailored to both small-molecule drugs and large-molecule biologics. The program addresses the unique challenges of regulated industries, including deviation management, analytical method variability, laboratory precision, aseptic processing concerns for parenterals, cell line stability, fermentation consistency, purification yield variation, and the hidden costs of poor quality. Participants will learn to move beyond simple specification conformance toward a culture of continuous, data-driven improvement that enhances both product quality and operational efficiency while maintaining full regulatory compliance. The program bridges the gap between technical statistical tools and the human elements of change management, recognizing that successful Six Sigma implementation requires both mathematical rigor and emotional intelligence.

Training Objectives

By completing this program, participants will be able to:

• Explain the complete historical evolution of quality thinking and the specific contributions of Six Sigma as a business strategy rather than merely a tactical tool.
• Distinguish between common-cause and special-cause variation in real-world pharmaceutical and biologic processes, and apply the appropriate management response to each.
• Construct, interpret, and utilize Shewhart control charts, including Average and Range charts and Individuals and Moving Range charts, to determine process stability and predictability across fermentation, purification, formulation, and filling operations.
• Apply the Taguchi Loss Function to justify investment in reducing variation, even when all products already meet established specifications or potency targets.
• Execute the five phases of the DMAIC methodology to solve chronic quality problems and reduce defects per million opportunities in both drug substance and drug product manufacturing.
• Integrate patient and customer requirements with process capabilities using structured tools, including Quality Function Deployment and Kano analysis.
• Reduce analytical variability in biologic quality control laboratories through control strategies, blind control studies, and standardized operator procedures for complex potency and purity assays.
• Design and implement process control plans that sustain improvements and maintain regulatory compliance with cGMP, ICH guidelines, and biologics-specific regulations.

Target Audience and Industry

Industry Focus: Pharmaceutical and biologics manufacturing, including small molecule drugs, large molecule biologics, vaccines, monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, blood products, and parenteral products. The principles also apply to pharmaceutical supply chain operations, distribution centers, cold chain management for biologics, and regulatory affairs functions.

Target Roles:

• Quality Assurance and Quality Control personnel at all levels
• Process and Manufacturing Engineers
• Compliance Officers and Regulatory Affairs Specialists
• Production Supervisors and Plant Managers
• Analytical Laboratory Managers and Scientists
• Continuous Improvement and Operational Excellence professionals
• Research and Development scientists transitioning to commercial manufacturing
• Upstream and Downstream Processing specialists in biologics
• Aseptic filling and sterile manufacturing operators

Regulatory and Compliance Framework for Pharmaceuticals and Biologics

This training complements existing regulatory obligations and is designed to enhance, not replace, compliance activities. Key frameworks that implicitly guide Six Sigma application include:

For Pharmaceuticals (Small Molecule Drugs):

• Current Good Manufacturing Practices (cGMP): 21 CFR Parts 210 and 211. Process stability and reduced variation directly support cGMP compliance by preventing deviations before they occur rather than investigating them after the fact.

For Biologics (Large Molecule Drugs, Vaccines, Gene Therapies, etc.):

• 21 CFR Part 600 (Biological Products: General Provisions): This regulation establishes standards for licensing biological products. It covers establishment standards, product safety, purity, potency, and labeling requirements. Six Sigma principles support compliance with Part 600 by reducing variation in critical quality attributes such as potency, purity, and safety profiles across lots.
• 21 CFR Part 610 (General Biological Products Standards): This regulation specifies general standards for biological products, including tests for potency, sterility, purity, and general safety. Six Sigma tools help biologics manufacturers consistently meet these standards by reducing analytical and process variation.
• 21 CFR Part 601 (Licensing of Biological Products): This regulation covers the submission of biologics license applications. Six Sigma methodologies applied during process development and validation provide robust data packages that support licensure.

Cross-Cutting ICH Guidelines Applicable to Both Pharmaceuticals and Biologics:

• ICH Q8 (Pharmaceutical Development): Emphasizes Quality by Design. Six Sigma tools for understanding variation, process capability, and design of experiments are fundamental to establishing a design space and defining a control strategy for both small molecules and biologics.
• ICH Q9 (Quality Risk Management): Supports risk-based decision making. Six Sigma data-driven analysis aligns with risk identification, analysis, evaluation, and control across all product types.
• ICH Q10 (Pharmaceutical Quality System): Describes the model for an effective pharmaceutical quality system. Six Sigma projects are a primary mechanism for achieving the continuous improvement pillar of this system.
• ICH Q5 (Quality of Biotechnological Products): Provides specific guidance for biologics, including viral safety, cell substrates, and stability testing. Six Sigma variation-reduction principles apply directly to these unique biological attributes.

FDA Guidance on Process Validation (2011): Emphasizes process design, process qualification, and continued process verification. Control charts and process capability analysis are essential tools for ongoing process verification for both pharmaceuticals and biologics. For biologics, this includes continuous verification of cell culture performance, purification yields, and product quality attributes.

Certification

Learners who successfully complete the program will receive a dated, traceable certificate that provides verifiable proof of their achievement for professional records.